Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Phase 3

Completed

Conditions: Lower Ureteric Stones

Interventions: Drug: Tamsulosin
Drug: Cetirizine
Combination Product: Cetirizine + Tamsulosin
Other: Placebo

First Posted Date: 2024-12-31

Last Posted Date: 2024-12-31

Lead Sponsor: South Valley University

Target Recruit Count: 480

Registration Number: NCT06754410

Locations: 🇪🇬
Qena university hospital, Qena, Egypt

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Phase 3

Recruiting

Conditions: Posterior Urethral Valve

Interventions: Drug: Oxybutynin
Drug: Tamsulosin
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-20

Lead Sponsor: Mansoura University

Target Recruit Count: 50

Registration Number: NCT06737016

Locations: 🇪🇬
Mansoura Urology and Nephrology Center, Mansoura, Dakahlia, Egypt

Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Not Applicable

Completed

Conditions: Lower Urinary Tract Symptoms
Prostatic Hyperplasia

Interventions: Drug: bovhyaluronidase azoximer
Drug: tamsulosin

First Posted Date: 2024-08-23

Last Posted Date: 2024-08-23

Lead Sponsor: NPO Petrovax

Target Recruit Count: 229

Registration Number: NCT06568718

Locations: 🇷🇺
LLC "Krasnodar Medical and Biological Center", Krasnodar, Russian Federation
🇷🇺
First Saint Petersburg State Medical University named after academician I.P. Pavlov, Saint Petersburg, Russian Federation
🇷🇺
LLC "Clinic of Modern Medicine of Dr. Bogorodskaya", Yaroslavl, Russian Federation

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial

Phase 2

Recruiting

Conditions: Urinary Retention Postoperative

Interventions: Drug: Tamsulosin Hydrochloride
Other: Placebo

First Posted Date: 2024-02-15

Last Posted Date: 2024-10-28

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 60

Registration Number: NCT06262048

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada

Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter

Phase 3

Recruiting

Conditions: Postoperative Urinary Tract Infection

Interventions: Other: Control Group
Drug: Tamsulosin

First Posted Date: 2024-02-14

Last Posted Date: 2024-03-06

Lead Sponsor: Emory University

Target Recruit Count: 212

Registration Number: NCT06257576

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital (EUH), Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States